Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Eloralintide

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Eli Lilly · Phase 2 · Active, not recruiting · Enrollment 200

NCT07215559

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Macupatide (Macupatide + Eloralintide Placebo)n/rn/rn/rn/r
Eloralintide (Elorlintide + Macupatide Placebo)n/rn/rn/rn/r
Macupatide + Eloralintiden/rn/rn/rn/r
Placebo (Macupatide Placebo + Elorlintide Placebo)n/rn/rn/rn/r

Not shown

  • Macupatide (Macupatide + Eloralintide Placebo): endpoint not reported
  • Eloralintide (Elorlintide + Macupatide Placebo): endpoint not reported
  • Macupatide + Eloralintide: endpoint not reported
  • Placebo (Macupatide Placebo + Elorlintide Placebo): endpoint not reported